The Food and Drug Administration on Tuesday approved the experimental Alzheimer's drug donanemab, which slowed the early stages of the fatal mind-robbing disease in studies.
The approval comes less than a month after an FDA advisory committee endorsed Eli Lilly's drug, despite questions from advisory committee members about the potential side effects of the drug. The drug is an antibody that removes beta-amyloid that accumulates in the brains of patients with Alzheimer's disease.
Eli Lilly said donanemab will be marketed under the brand name Kisunla as a monthly injection, which will be administered via IV infusion. The Alzheimer's treatment will be available for adults with early symptoms of Alzheimer's disease, which includes mild cognitive impairment and mild dementia. Patients will be tested for amyloid before starting the medication.
Taking a daily multivitamin does not help people to live any longer and may actually increase...
